Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib in Advanced Sarcomas
NCT06571734Phase 2Recruiting
- Sponsor
- Northwestern University
- Start
- Sep 2024
- Primary completion
- Jul 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib, sponsored by Northwestern University. Started Sep 2024; status: recruiting.
02
Drugs
zanzalintinib
Beyond the preview
Go deeper on NCT06571734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571734.